Persistent complement activation on tumor cells in breast cancer.
about
The dual role of complement in cancer and its implication in anti-tumor therapyMembrane attack by complement: the assembly and biology of terminal complement complexesBlood peptidome-degradome profile of breast cancerPlasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells.Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infectionMicroRNA-centric measurement improves functional enrichment analysis of co-expressed and differentially expressed microRNA clustersBreast cancer subtyping from plasma proteins.Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells.Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.The role of complement in tumor growthComplement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.Ascitic complement system in ovarian cancerIs complement good or bad for cancer patients? A new perspective on an old dilemma.Unwelcome complement.C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy.CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.Can IgA, C3, IL-6 and TNF-α act as predictors for reoccurrence of breast cancer among Iraqi women?Complement inhibition in cancer therapy.The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.The role of the complement system in cancer.Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomasRegulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.Expression of complement regulating factors in gastric cancer cells.Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.Targeting complement-mediated immunoregulation for cancer immunotherapy.Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression.Complement as a Biological Tool to Control Tumor Growth
P2860
Q26738682-AD082FD8-8137-4D38-A47E-55E13D6D25BDQ26997385-C30C5086-DDB1-4BA4-9DEF-7025A10D522AQ28475815-264938C2-2BA5-45F1-A8AC-D08AB4D844CBQ33453474-5921ABD0-700E-4F9A-B832-2A592CED3C5AQ34000677-C66CDA17-1513-4A17-99DB-6699E6E15673Q34257818-B64ADEC0-C53D-4CB0-9DF0-946BB76658BCQ34529701-BEABFC40-6E20-411A-984F-F4A8C2AB0D3FQ34570193-3ED6A9AB-4723-4A61-ADB8-2E230F7B87B4Q34733788-53E7F0B8-5480-4D39-83B0-DFD2E7817D3AQ35036132-081758B2-2FAE-4707-BA51-E0EE5439F3B9Q35060303-5D4D88BE-189A-430B-82C9-21EB9A14F501Q35231345-6976CDC0-26DC-4388-9602-8C410F1F03B5Q35536219-4571AAB8-6292-4EF9-9C32-93B398280D44Q35782339-CABBA94B-52D6-4F71-8A5D-35784AD5AF0FQ36338990-21E69EDF-BD6A-4614-9EC0-DDE2398ED348Q36616364-09DFBA9A-9C21-4937-88A0-654ECA310772Q37247425-177392AC-1881-4C96-888C-138BE85EB0D0Q37306936-E1208924-B674-45C0-BCC2-69DEC2F08D4FQ37407271-313B8724-F8D0-4823-8168-37B46E179153Q37583589-B343CB3A-B1C6-4175-9DC0-6E97BDD7F198Q37709507-49B293EA-D3B8-44D0-B4AC-12953882C665Q38109340-56E59B16-89E3-41A6-9A85-C0D382EDF8D7Q38715342-F0BCC7E6-ED71-42D0-B7D7-441F9C3D9934Q38768372-A6445906-C3B3-48ED-8E43-61BC1F0B9904Q39156024-15D1DB61-68AD-4CB6-902D-3571728DA43BQ39317804-4A371553-FCFB-4BA8-AA5B-BAE354ACEFC7Q40074732-D3FC3191-2270-4542-86C5-D686C0A13E90Q40522463-E4BFCA6A-0476-420E-9314-0771BD1A6B37Q40975346-7A3E716D-C25B-426F-89E6-F0F44977EDEAQ42937477-773AA448-26B9-4C8C-9662-8525184C3E7FQ47148148-56C537BC-6203-42AB-997B-E520A1D52725Q49898514-811A9907-6752-49AB-BC85-CEE3138898FDQ55024293-99C17ED5-03C5-4074-AA35-E074A536FFDAQ57492005-A6E84DEB-39CB-4D63-B974-6C67C4293784
P2860
Persistent complement activation on tumor cells in breast cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Persistent complement activation on tumor cells in breast cancer.
@ast
Persistent complement activation on tumor cells in breast cancer.
@en
type
label
Persistent complement activation on tumor cells in breast cancer.
@ast
Persistent complement activation on tumor cells in breast cancer.
@en
prefLabel
Persistent complement activation on tumor cells in breast cancer.
@ast
Persistent complement activation on tumor cells in breast cancer.
@en
P2093
P2860
P1476
Persistent complement activation on tumor cells in breast cancer.
@en
P2093
P2860
P304
P407
P577
1992-05-01T00:00:00Z